A prediction model of liver fat fraction and presence of non-alcoholic fatty liver disease (NAFLD) among patients with overweight or obesity

被引:1
作者
Chen, Jie [1 ]
Yue, Jiang [1 ]
Fu, Jingjing [1 ]
He, Shengyun [2 ]
Liu, Qianjing [1 ]
Yang, Minglan [1 ]
Zhang, Wang [1 ]
Xu, Hua [1 ]
Lu, Qing [2 ,4 ]
Ma, Jing [1 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Endocrinol & Metab, Shanghai 200127, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiol, Shanghai 200127, Peoples R China
[3] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Endocrinol & Metab, 160 Pujian Rd, Shanghai 200127, Peoples R China
[4] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiol, 160 Pujian Rd, Shanghai 200127, Peoples R China
关键词
Non-alcoholic fatty liver disease (NAFLD); Magnetic resonance imaging proton density fat fraction (MRI-PDFF); Obese; Overweight; HEPATIC STEATOSIS; DIAGNOSIS; PREVALENCE; BIOPSY;
D O I
10.1507/endocrj.EJ23-0227
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The global prevalence of non-alcoholic fatty liver disease (NAFLD) has attained a level of 25.24%. The prevalence of NAFLD in China has exhibited an upward trajectory in parallel with the increasing incidence of obesity over the preceding decade. In order to comprehensively assess hepatic lipid deposition in individuals with overweight or obesity, we have devised a pioneering prognostic formula that capitalizes on clinical parameters. To this end, we have conducted a cross-sectional cohort study involving 149 overweight or obese subjects. Magnetic resonance imaging proton density fat fraction (MRI-PDFF) has been employed to evaluate the extent of liver fat accumulation. Through univariate analysis, we have identified potential factors, and the definitive elements in the prediction model were selected utilizing the forward stepwise regression algorithm. The Shang Hai Steatosis Index (SHSI) incorporates alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting insulin, and 1-h postload glycaemic levels, thereby furnishing the capability to predict NAFLD with an area under the receiver operator characteristic (AUROC) of 0.87. By establishing a threshold value of 10.96, determined through Youden's index, we have achieved a sensitivity of 69.57% and a specificity of 88.24%. The Spearman correlation coefficient between liver fat fraction ascertained by MRI-PDFF and that predicted by the SHSI equation amounts to 0.74. Consequently, the SHSI equation affords a dependable means of predicting the presence of NAFLD and liver fat accumulation within the overweight and obese population.
引用
收藏
页码:977 / 985
页数:9
相关论文
共 50 条
  • [21] Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
    Rong, Li
    Zou, Junyan
    Ran, Wei
    Qi, Xiaohong
    Chen, Yaokai
    Cui, Hongjuan
    Guo, Jinjun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 13
  • [22] Pathology of non-alcoholic fatty liver disease
    Cataldo, Ivana
    Sarcognato, Samantha
    Sacchi, Diana
    Cacciatore, Matilde
    Baciorri, Francesca
    Mangia, Alessandra
    Cazzagon, Nora
    Guido, Maria
    PATHOLOGICA, 2021, 113 (03) : 194 - 202
  • [23] Serum adipokine levels in overweight patients and their relationship with non-alcoholic fatty liver disease
    Abenavoli, L.
    Luigiano, C.
    Guzzi, P. H.
    Milic, N.
    Morace, C.
    Stelitano, L.
    Consolo, P.
    Miraglia, S.
    Fagoonee, S.
    Virgilio, C.
    Luzza, F.
    De Lorenzo, A.
    Pellicano, R.
    PANMINERVA MEDICA, 2014, 56 (02) : 189 - 193
  • [24] Non-alcoholic fatty liver disease
    Maurice, James
    Manousou, Pinelopi
    CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250
  • [25] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [26] Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
    Kotronen, Anna
    Peltonen, Markku
    Hakkarainen, Antti
    Sevastianova, Ksenia
    Bergholm, Robert
    Johansson, Lina M.
    Lundbom, Nina
    Rissanen, Aila
    Ridderstrale, Martin
    Groop, Leif
    Orho-Melander, Marju
    Yki-Jarvinen, Hannele
    GASTROENTEROLOGY, 2009, 137 (03) : 865 - 872
  • [27] Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
    Yao, Pengyu
    Liu, Yajuan
    MOLECULES, 2023, 28 (01):
  • [28] Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD)
    Choudhary, Narendra Singh
    Duseja, Ajay
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 6
  • [29] Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
    Riazi, Kiarash
    Swain, Mark G.
    Congly, Stephen E.
    Kaplan, Gilaad G.
    Shaheen, Abdel-Aziz
    NUTRIENTS, 2022, 14 (21)
  • [30] Agai improves non-alcoholic fatty liver disease (NAFLD) induced by fructose
    de Freitas Carvalho, Mayara Medeiros
    Teixeira Reis, Larissa Lelis
    Macedo Lopes, Juliana Marcia
    Lage, Nara Nunes
    da Costa Guerra, Joyce Ferreira
    Zago, Helena Porto
    Bonomo, Larissa de Freitas
    Pereira, Renata Rebeca
    de Lima, Wanderson Geraldo
    Silva, Marcelo Eustaquio
    Pedrosa, Maria Lucia
    NUTRICION HOSPITALARIA, 2018, 35 (02) : 318 - 325